Emory University: Carcinoma, Non-Small-Cell Lung trials

The registry lists 11 Carcinoma, Non-Small-Cell Lung studies with Emory University as lead sponsor. 3 are open to participants now and 3 have results posted.

Early Phase 1 1Phase 1 6Phase 2 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent ImmunotherapyRecruitingNCT06731270Phase 2
• Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung CancerRecruitingNCT05493566Early Phase 1
• MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung CancerRecruitingNCT04762199Phase 1
• Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell CarcinomaTerminatedNCT04495894Phase 2Results posted
• Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung CancerTerminatedNCT04348292Phase 1Results posted
• Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain MetastasesCompletedNCT02858869Phase 1Results posted
• Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung CancerWithdrawnNCT04262869Phase 2
• Fludeoxyglucose F-18-PET in Planning Lung Cancer Radiation TherapyCompletedNCT03493789Phase 1
• Nivolumab in Treating Patients With Advanced Metastatic Non-small Cell Lung CancerWithdrawnNCT03121417Phase 2
• Palbociclib With Cisplatin or Carboplatin in Advanced Solid TumorsCompletedNCT02897375Phase 1
• An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)Status unknownNCT01711697Phase 1